Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance
23 May 2024 - 10:05PM
Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics
contract development and manufacturing organization (CDMO) working
to improve patient lives by providing high quality development and
manufacturing services to biotechnology and pharmaceutical
companies, today announced that the company has achieved a
Committed Badge from EcoVadis, one of the world’s most trusted
providers of business sustainability ratings. Avid earned a score
of 56 from EcoVadis, placing the company in the 62nd percentile
globally.
“We are pleased to be recognized for our
commitment to sustainability. This impressive rating by EcoVadis
validates the effort and performance of our team in integrating a
focus on sustainability into our day-to-day business activities,”
said Nick Green, president and CEO of Avid Bioservices. “While we
are happy to be acknowledged for our work in this area, we
recognize that sustainability is an ongoing effort, and we will
continue to seek opportunities to improve our performance moving
forward.”
EcoVadis is the global standard for business
sustainability ratings. The EcoVadis assessment evaluates 21
sustainability criteria across four core themes: Environment, Labor
& Human Rights, Ethics and Sustainable Procurement. More than
125,000 companies globally have been rated by EcoVadis.
EcoVadis’ business sustainability ratings are
based on international sustainability standards such as the Ten
Principles of the UN Global Compact, the International Labour
Organization (ILO) conventions, the Global Reporting Initiative
(GRI) standards and the ISO 26000 standard. The ratings provide an
evidenced-based analysis on performance and an actionable roadmap
for continuous improvement. Learn more at
www.EcoVadis.com/suppliers
About Avid Bioservices, Inc.
Avid Bioservices (NASDAQ: CDMO) is a
dedicated contract development and manufacturing organization
(CDMO) focused on development and CGMP manufacturing of biologics.
The company provides a comprehensive range of process development,
CGMP clinical and commercial manufacturing services for the
biotechnology and biopharmaceutical industries. With more than 30
years of experience producing biologics, Avid's services include
CGMP clinical and commercial drug substance manufacturing, bulk
packaging, release and stability testing and regulatory submissions
support. For early-stage programs the company provides a variety of
process development activities, including cell line development,
upstream and downstream development and optimization, analytical
methods development, testing and characterization. The scope
of our services ranges from standalone process development projects
to full development and manufacturing programs through
commercialization. www.avidbio.com
Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Avid Bioservices (NASDAQ:CDMOP)
Historical Stock Chart
From Nov 2024 to Dec 2024
Avid Bioservices (NASDAQ:CDMOP)
Historical Stock Chart
From Dec 2023 to Dec 2024